Immunotherapy’s Success in the Battle Against Mesothelioma

Discover groundbreaking developments in mesothelioma treatment unveiled at the National Congress of the Scientific Society in Rome. The IND.227 study, featured in “The Lancet,” involved 440 patients across 51 international centers and provided fresh insights into pleural mesothelioma, a highly aggressive thoracic tumor. Notably, the study showcased a paradigm shift, demonstrating that 25% of patients survived three years post-diagnosis, thanks to a novel combination of immunotherapy and chemotherapy.

Read the article »